|PULM -- USA Stock|| |
USD 0.57 0.05 10.64%
Mr. Terrance G. McGuire is Independent Director of the Company. Mr. McGuire was previously a director of Pulmatrix Operating from May 2006 until the date of the Merger. Mr. McGuire cofounded Polaris Partners in 1996 and is currently one of their General Partners. Prior to starting Polaris Partners, Mr. McGuire spent seven years at Burr, Egan, Deleage Co., investing in early stage medical and information technology companies. He currently serves on the board of directors of two public companies Acceleron Pharma Inc. and Ironwood Pharmaceuticals Inc. Mr. McGuire also serves on the boards of several private companies, including Adimab, Alector, Quantum Designs, Inc., Arsenal Medical480 Biomedical, Iora Health and MicroCHIPS. Mr. McGuire has formerly served on the board of directors of Editas, Life Line Screening, NextCode, Trevena and Saga, among others. Mr. McGuire is the former chairman of the National VC Association, chairman of the board of the Thayer School of Engineering at Dartmouth College, and a member of the boards of The David H. Koch Institute for Integrative Cancer Research at the Massachusetts Institute of Technology and The Arthur Rock Center for Entrepreneurship at Harvard Business School
Age: 60 Director Since 2015 MBA
McGuire earned a B.S. in physics and economics from Hobart College, an M.S. in engineering from The Thayer School at Dartmouth College, and an M.B.A. from Harvard Business School.
Terrance McGuire Latest Insider Activity
The company has return on total asset (ROA)
of (65.98) %
which means that it has lost $65.98 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE)
of (168.96) %
meaning that it created substantial loss on money invested by shareholders.
The company currently holds 2.52 M in liabilities with Debt to Equity (D/E) ratio of 33.5 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Pulmatrix has Current Ratio of 0.32 indicating that it has a negative working capital and may not be able to pay financial obligations when they are due.
Pulmatrix, Inc., a clinical stage biopharmaceutical company, develops inhaled therapies to address serious pulmonary diseases using its inhaled Small Particles Easily Respirable and Emitted technology. Pulmatrix, Inc. was founded in 2003 and is headquartered in Lexington, Massachusetts. Pulmatrix operates under Biotechnology classification in USA and traded on NASDAQ General Markets. It employs 24 people.Pulmatrix (PULM) is traded on NASDAQ General Markets in USA. It is located in MASSACHUSETTS, U.S.A and employs 24 people. Pulmatrix is listed under Pharmaceutical Products category by Fama And French industry classification.
Pulmatrix Leadership Team
|Terrance McGuire, Director, MBA|
|Matthew Sherman, Director|
|David Hava, Executive, Ph.D|
|Akihisa Akao, Director|
|James Roach, Executive, Ph.D|
|Michael Higgins, Director, MBA|
|Steven Gillis, Director|
|Jean Sung, President|
|William Duke, CFO, MBA|
|Robert Clarke, CEO, Ph.D|
|Scott Rocklage, Director, Ph.D|
|Kurt Graves, Director|
|Richard Conley, Director, MBA|
|Mark Iwicki, Chairman, MBA|
|Amit Munshi, Director, MBA|
|Gregory French, Director|
|David JD, Executive|
Stock Performance Indicators
Most of Macroaxis users are at this time bullish on Pulmatrix. What is your perspective on investing in Pulmatrix? Are you bullish or bearish?
Additionally take a look at Your Equity Center
. Please also try Money Flow Index
module to determine momentum by analyzing money flow index and other technical indicators.